Navigation Links
Hydrophilic Tubing Filter (clear PVC)

ProductsHydrophilic Tubing Filter (clear PVC)
Company Portex
Item Hydrophilic Tubing Filter (clear PVC)
Features 
  • Portex® filters provide the finest in protection, cost control, flexibility, and ease of use.
  • Filters are available for use with mechanical ventilators, anesthesia machines, and open flow systems
  • 20 units per case
  • Our filters offer bacterial/viral efficiency ratings up to 99.99999% (data on file)
Description The Portex® Thermovent® T helps provide protection to the exposed airway of the tracheostomy patient. It is small and extremely lightweight making it ideal for active young children as well as adults. With a high rate of heat and moisture recovery, it ensures patient comfort and reduces secretion retention.

All HMEs and filters have ISO standard tapered ends to assure a consistent leak-free seal.

All Portex® HMEs and filters are latex-free.
Info Portex
Customer Service: (603) 352-3812
Web site: http://www.smiths-medical.com

Related medicine products :

1. FLEXOR TUOHY-BORST Side-Arm Introducers ANSEL Modification with Radiopaque Band and AQ Hydrophilic Coating
2. Foldable Hydrophilic IOL with UV Absorber
3. NaturaLens™ Series Hydrophilic Acrylic Intraocular Lens
4. HAPTIBAG Hydrophilic Acrylic Lens
5. TRIPODE Hydrophilic Acrylic Lens
6. XL OCTO Hydrophilic Acrylic Lens
7. BIGBAG Hydrophilic Acrylic Lens
8. XL STABI Hydrophilic Acrylic Lens
9. STABIBAG Hydrophilic Acrylic Lens
10. NaturaLens™ Series Hydrophilic Acrylic Intraocular Lens (Refractive and Bifocal)
11. Clo-Sur P.A.D. Nonwoven Hydrophilic Wound Dressing
MagaCell-Streptavidin is a streptavidin coupled to magnetizable cellulose/iron oxide particles
BioVintages Biotin-Trapper™ Streptavidin Magnetic Beads (1 mm - 2 mm) are designed for single-step capture of biotinylated molecules such as DNA, RNA or protein from cell lysates or hybridizatio
Magnetic separation is a method for isolating antibodies, antigens, lectins, enzymes, nucleic acids and cells using affinity binding, while retaining biological activity. Streptavidin has been coated
1 m Dynabeads with covalently bound recombinant streptavidin, allowing capture of any biotinylated target. The Dynabeads® MyOne™ have a large surface area, high capacity, magnetic pull and
Medicine Products:
(Date:5/16/2008)...ns of Children Still in Danger, NEW YORK, May 16 ...dvertising Council today announced a partnership t...ic service announcements (PSAs) filmed by A-List,c... Joel Madden, David,Duchovny, Tea Leoni, and Paul ...r cyclone. The Ad Council is distributing the new ...
(Date:5/16/2008)...wswire-FirstCall/ -- Nationwide,Health Properties,...of David,M. Boitano to Senior Vice President and S...ous contribution to NHP over the last several year... diversification strategy,successes. Dave has been...stments for NHP, leveraging his vast experience an...
(Date:5/16/2008)...Call/ -- CryoCor, Inc. (Nasdaq:,CRYO), a medical d...arrhythmias, announced today that on May 8, 2008, ...a complaint in the Superior Court of the State,of ...nts each member of the,Board of Directors of CryoC... complaint is styled Secondido, et al. v. CryoCor,...
(Date:5/16/2008)...ed to community physicians, audit finds , ...s between major academic cancer centers and commun...ead cancer treatment advances, say researchers at ... new cancer treatments are created at major academ...munity hospitals, noted the researchers, who condu...
Breaking Medicine News(10 mins):Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 2Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 3Health News:David M. Boitano Promoted to Senior Vice President 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 3Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 4Health News:Partnerships Effective Communicators of Cancer Advances 2
...th crisis in the Palestinian territory following t...he UN health agency has called for urgent action b...n of basic medical services. "The crisis is seriou...tinian Ministry of Health to deliver critical heal...
...apathy, has been appointed honorary consultant and...vices in speciality of plastic, hand and reconstru...ead of the Department of surgery in Ganga Medical ...consultation and perform major operations to membe...
...od protein levels are found to be associated with ...es// , metabolic syndrome and cardiovascular disea...inding protein 4 (RBP4), when reduced by the effec...s proved to drop the risk factors of diabetes – fi...
...issioned by The Globe and Mail and CTV News it is ...rans fats that are among the highest in the world/...When surveyed the different outlets of fast foods ...it was found that the amount of trans fat in these...
Other Medicine News:Health News:A Carrier Protein Associates With Human Insulin Resistance 2
(Date:5/15/2008)...May 15 /- Medivation, Inc.,... ongoing Phase 1-2 clinical,trial of its novel and...ted,in an oral presentation at the 44th American S...in Chicago., Session title: New Targeted Strate...te and time: Monday, June 2 at 11:30 a.m. Central ...
(Date:5/15/2008)...ed amount of research reflects depth and breadth o...develop new treatments for ...hlight impact of Zometa(R), the leading IV, bispho...tage breast cancer, - Four oral sessions to featu...itor of mTOR, including first results of RECORD-1 ...
(Date:5/15/2008).... and TOULOUSE, France, May 15 /- Cer...harmaceutical company,developing HDL-related compo...olic diseases, today announced that it has complet...e company,s lead product candidates.,CER-002 is a ...delta-specific agonist in development for the trea...
(Date:5/15/2008)...unity Remains for an Antiplatelet Therapy that, Co...e Combination of Plavix/Iscover and Aspirin, A... WALTHAM, Mass., May 15 /- Decision R...advisory firms for pharmaceutical and,healthcare i...nt offers,improvement in patient compared to Sanof...
Breaking Medicine Technology:Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 2Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Coley Pharmaceutical Group Adopts Shareholder Rights Plan 1116 1Coley Pharmaceutical Group Adopts Shareholder Rights Plan 1116 2Coley Pharmaceutical Group Adopts Shareholder Rights Plan 1116 3Enrollment Complete in Pivotal Phase 3 Trial of Medidur 28TM 29 FA for Diabetic Macular Edema 462 1Enrollment Complete in Pivotal Phase 3 Trial of Medidur 28TM 29 FA for Diabetic Macular Edema 462 2Enrollment Complete in Pivotal Phase 3 Trial of Medidur 28TM 29 FA for Diabetic Macular Edema 462 3Enrollment Complete in Pivotal Phase 3 Trial of Medidur 28TM 29 FA for Diabetic Macular Edema 462 4American Chemical Societys Weekly PressPac Oct 3 2007 709 1American Chemical Societys Weekly PressPac Oct 3 2007 709 2American Chemical Societys Weekly PressPac Oct 3 2007 709 3American Chemical Societys Weekly PressPac Oct 3 2007 709 4American Chemical Societys Weekly PressPac Oct 3 2007 709 5American Chemical Societys Weekly PressPac Oct 3 2007 709 6American Chemical Societys Weekly PressPac Oct 3 2007 709 7American Chemical Societys Weekly PressPac Oct 3 2007 709 8Mylan Inc Subsidiary Dey L P Announces that Perforomist 28TM 29 28Formoterol Fumarate 29 Inhalation Solution is Now Available for Maintenance Tr 1113 1Mylan Inc Subsidiary Dey L P Announces that Perforomist 28TM 29 28Formoterol Fumarate 29 Inhalation Solution is Now Available for Maintenance Tr 1113 2Mylan Inc Subsidiary Dey L P Announces that Perforomist 28TM 29 28Formoterol Fumarate 29 Inhalation Solution is Now Available for Maintenance Tr 1113 3Mylan Inc Subsidiary Dey L P Announces that Perforomist 28TM 29 28Formoterol Fumarate 29 Inhalation Solution is Now Available for Maintenance Tr 1113 4Mylan Inc Subsidiary Dey L P Announces that Perforomist 28TM 29 28Formoterol Fumarate 29 Inhalation Solution is Now Available for Maintenance Tr 1113 5Mylan Inc Subsidiary Dey L P Announces that Perforomist 28TM 29 28Formoterol Fumarate 29 Inhalation Solution is Now Available for Maintenance Tr 1113 6